Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 173

1.

5-Fluorouracil adjuvant chemotherapy does not increase survival in patients with CpG island methylator phenotype colorectal cancer.

Jover R, Nguyen TP, Pérez-Carbonell L, Zapater P, Payá A, Alenda C, Rojas E, Cubiella J, Balaguer F, Morillas JD, Clofent J, Bujanda L, Reñé JM, Bessa X, Xicola RM, Nicolás-Pérez D, Castells A, Andreu M, Llor X, Boland CR, Goel A.

Gastroenterology. 2011 Apr;140(4):1174-81. doi: 10.1053/j.gastro.2010.12.035. Epub 2010 Dec 24.

2.

CpG island methylator phenotype is associated with response to adjuvant irinotecan-based therapy for stage III colon cancer.

Shiovitz S, Bertagnolli MM, Renfro LA, Nam E, Foster NR, Dzieciatkowski S, Luo Y, Lao VV, Monnat RJ Jr, Emond MJ, Maizels N, Niedzwiecki D, Goldberg RM, Saltz LB, Venook A, Warren RS, Grady WM; Alliance for Clinical Trials in Oncology.

Gastroenterology. 2014 Sep;147(3):637-45. doi: 10.1053/j.gastro.2014.05.009. Epub 2014 May 21.

3.

Evaluation of CpG Island Methylator Phenotype as a Biomarker in Colorectal Cancer Treated With Adjuvant Oxaliplatin.

Cohen SA, Wu C, Yu M, Gourgioti G, Wirtz R, Raptou G, Gkakou C, Kotoula V, Pentheroudakis G, Papaxoinis G, Karavasilis V, Pectasides D, Kalogeras KT, Fountzilas G, Grady WM.

Clin Colorectal Cancer. 2016 Jun;15(2):164-9. doi: 10.1016/j.clcc.2015.10.005. Epub 2015 Nov 11.

4.

CpG island methylator phenotype is an independent predictor of survival benefit from 5-fluorouracil in stage III colorectal cancer.

Van Rijnsoever M, Elsaleh H, Joseph D, McCaul K, Iacopetta B.

Clin Cancer Res. 2003 Aug 1;9(8):2898-903.

5.

Methylation and microsatellite status and recurrence following adjuvant FOLFOX in colorectal cancer.

Han SW, Lee HJ, Bae JM, Cho NY, Lee KH, Kim TY, Oh DY, Im SA, Bang YJ, Jeong SY, Park KJ, Park JG, Kang GH, Kim TY.

Int J Cancer. 2013 May 1;132(9):2209-16. doi: 10.1002/ijc.27888. Epub 2012 Oct 29.

6.

Prognostic value of CpG island methylator phenotype among colorectal cancer patients: a systematic review and meta-analysis.

Juo YY, Johnston FM, Zhang DY, Juo HH, Wang H, Pappou EP, Yu T, Easwaran H, Baylin S, van Engeland M, Ahuja N.

Ann Oncol. 2014 Dec;25(12):2314-27. doi: 10.1093/annonc/mdu149. Epub 2014 Apr 8. Review.

7.

The CpG island methylator phenotype may confer a survival benefit in patients with stage II or III colorectal carcinomas receiving fluoropyrimidine-based adjuvant chemotherapy.

Min BH, Bae JM, Lee EJ, Yu HS, Kim YH, Chang DK, Kim HC, Park CK, Lee SH, Kim KM, Kang GH.

BMC Cancer. 2011 Aug 10;11:344. doi: 10.1186/1471-2407-11-344.

8.

Nuclear maspin expression correlates with the CpG island methylator phenotype and tumor aggressiveness in colorectal cancer.

Kim JH, Cho NY, Bae JM, Kim KJ, Rhee YY, Lee HS, Kang GH.

Int J Clin Exp Pathol. 2015 Feb 1;8(2):1920-8. eCollection 2015.

9.

Long interspersed nuclear element-1 hypomethylation is a potential biomarker for the prediction of response to oral fluoropyrimidines in microsatellite stable and CpG island methylator phenotype-negative colorectal cancer.

Kawakami K, Matsunoki A, Kaneko M, Saito K, Watanabe G, Minamoto T.

Cancer Sci. 2011 Jan;102(1):166-74. doi: 10.1111/j.1349-7006.2010.01776.x. Epub 2010 Nov 19.

10.

The role of the CpG island methylator phenotype on survival outcome in colon cancer.

Kang KJ, Min BH, Ryu KJ, Kim KM, Chang DK, Kim JJ, Rhee JC, Kim YH.

Gut Liver. 2015 Mar;9(2):202-7. doi: 10.5009/gnl13352.

11.

CpG island methylation, response to combination chemotherapy, and patient survival in advanced microsatellite stable colorectal carcinoma.

Ogino S, Meyerhardt JA, Kawasaki T, Clark JW, Ryan DP, Kulke MH, Enzinger PC, Wolpin BM, Loda M, Fuchs CS.

Virchows Arch. 2007 May;450(5):529-37. Epub 2007 Mar 20.

PMID:
17372756
12.

Are clinicopathological features of colorectal cancers with methylation in half of CpG island methylator phenotype panel markers different from those of CpG island methylator phenotype-high colorectal cancers?

Bae JM, Rhee YY, Kim KJ, Wen X, Song YS, Cho NY, Kim JH, Kang GH.

Hum Pathol. 2016 Jan;47(1):85-94. doi: 10.1016/j.humpath.2015.09.008. Epub 2015 Sep 25.

PMID:
26520418
13.

CpG island methylator phenotype identifies high risk patients among microsatellite stable BRAF mutated colorectal cancers.

Vedeld HM, Merok M, Jeanmougin M, Danielsen SA, Honne H, Presthus GK, Svindland A, Sjo OH, Hektoen M, Eknaes M, Nesbakken A, Lothe RA, Lind GE.

Int J Cancer. 2017 Sep 1;141(5):967-976. doi: 10.1002/ijc.30796. Epub 2017 Jun 2.

14.

Predicting clinical outcome of 5-fluorouracil-based chemotherapy for colon cancer patients: is the CpG island methylator phenotype the 5-fluorouracil-responsive subgroup?

Iacopetta B, Kawakami K, Watanabe T.

Int J Clin Oncol. 2008 Dec;13(6):498-503. doi: 10.1007/s10147-008-0854-3. Epub 2008 Dec 18. Review.

PMID:
19093176
15.

The efficacy of adjuvant chemotherapy with 5-fluorouracil in colorectal cancer depends on the mismatch repair status.

Jover R, Zapater P, Castells A, Llor X, Andreu M, Cubiella J, Balaguer F, Sempere L, Xicola RM, Bujanda L, Reñé JM, Clofent J, Bessa X, Morillas JD, Nicolás-Pérez D, Pons E, Payá A, Alenda C; Gastrointestinal Oncology Group of the Spanish Gastroenterological Association.

Eur J Cancer. 2009 Feb;45(3):365-73. doi: 10.1016/j.ejca.2008.07.016. Epub 2008 Aug 21.

PMID:
18722765
16.

No association of CpG island methylator phenotype and colorectal cancer survival: population-based study.

Jia M, Jansen L, Walter V, Tagscherer K, Roth W, Herpel E, Kloor M, Bläker H, Chang-Claude J, Brenner H, Hoffmeister M.

Br J Cancer. 2016 Nov 22;115(11):1359-1366. doi: 10.1038/bjc.2016.361. Epub 2016 Nov 3.

PMID:
27811854
17.

Management of stage II colon cancer - the use of molecular biomarkers for adjuvant therapy decision.

Donada M, Bonin S, Barbazza R, Pettirosso D, Stanta G.

BMC Gastroenterol. 2013 Feb 27;13:36. doi: 10.1186/1471-230X-13-36.

18.

DNA mismatch repair status and colon cancer recurrence and survival in clinical trials of 5-fluorouracil-based adjuvant therapy.

Sinicrope FA, Foster NR, Thibodeau SN, Marsoni S, Monges G, Labianca R, Kim GP, Yothers G, Allegra C, Moore MJ, Gallinger S, Sargent DJ.

J Natl Cancer Inst. 2011 Jun 8;103(11):863-75. doi: 10.1093/jnci/djr153. Epub 2011 May 19. Erratum in: J Natl Cancer Inst. 2011 Nov 2;103(21):1639. Kim, George P [added].

19.

Prognostic and predictive value of CpG island methylator phenotype in patients with locally advanced nonmetastatic sporadic colorectal cancer.

Wang Y, Long Y, Xu Y, Guan Z, Lian P, Peng J, Cai S, Cai G.

Gastroenterol Res Pract. 2014;2014:436985. doi: 10.1155/2014/436985. Epub 2014 Jan 14. Erratum in: Gastroenterol Res Pract. 2014;2014:418148.

20.

DNMT3B expression might contribute to CpG island methylator phenotype in colorectal cancer.

Nosho K, Shima K, Irahara N, Kure S, Baba Y, Kirkner GJ, Chen L, Gokhale S, Hazra A, Spiegelman D, Giovannucci EL, Jaenisch R, Fuchs CS, Ogino S.

Clin Cancer Res. 2009 Jun 1;15(11):3663-71. doi: 10.1158/1078-0432.CCR-08-2383. Epub 2009 May 26.

Supplemental Content

Support Center